Curanex Pharma Files S-1/A for IPO
Ticker: CURX · Form: S-1/A · Filed: Mar 17, 2025 · CIK: 2025942
| Field | Detail |
|---|---|
| Company | Curanex Pharmaceuticals Inc (CURX) |
| Form Type | S-1/A |
| Filed Date | Mar 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: ipo, pharmaceuticals, sec-filing
TL;DR
Curanex Pharma just filed an S-1/A for their IPO. Looks like they're going public.
AI Summary
Curanex Pharmaceuticals Inc. filed an S-1/A amendment on March 17, 2025, for its initial public offering. The company, incorporated in Nevada and based in Jericho, NY, is seeking to register an unspecified number of shares under the Securities Act of 1933. The filing details its principal executive offices and agent for service, with Jun Liu listed as Chief Executive Officer.
Why It Matters
This S-1/A filing indicates Curanex Pharmaceuticals is moving forward with its plans to become a publicly traded company, which could lead to increased investment and development in its pharmaceutical products.
Risk Assessment
Risk Level: medium — As a pharmaceutical company undergoing an IPO, Curanex faces typical risks associated with clinical trials, regulatory approvals, and market competition, alongside the inherent uncertainties of a new public offering.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
- 830741390 — IRS Number (Company's Employer Identification Number)
Key Players & Entities
- Curanex Pharmaceuticals Inc (company) — Registrant
- March 17, 2025 (date) — Filing date
- 2 Jericho Plaza, Suite 101B Jericho, NY 11753 (location) — Principal executive offices
- Jun Liu (person) — Chief Executive Officer
- 333-282686 (registration_number) — SEC registration number
FAQ
What is the primary purpose of this S-1/A filing?
The S-1/A filing is an amendment to Curanex Pharmaceuticals Inc.'s registration statement for its initial public offering (IPO) under the Securities Act of 1933.
When was this amendment filed with the SEC?
This amendment was filed with the Securities and Exchange Commission on March 17, 2025.
Who is the Chief Executive Officer of Curanex Pharmaceuticals Inc.?
Jun Liu is listed as the Chief Executive Officer of Curanex Pharmaceuticals Inc.
What is the principal business address of Curanex Pharmaceuticals Inc.?
The principal executive offices are located at 2 Jericho Plaza, Suite 101B, Jericho, NY 11753.
In which state was Curanex Pharmaceuticals Inc. incorporated?
Curanex Pharmaceuticals Inc. was incorporated in Nevada.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on March 17, 2025 by Jun Liu regarding Curanex Pharmaceuticals Inc (CURX).